Incyclix Bio is a next-generation cell cycle control company, advancing precision treatments that target the aberrant proliferation driving many cancers.
Research Triangle Park, NC
Joined March 2022
- Tweets78
- Following128
- Followers32
- Likes3
~170K people in the U.S. are living with #metastaticbreastcancer, making the need for new treatments significant.
Learn more about our novel, potent #CDK2 inhibitor INX-315 for advanced #breastcancer:
incyclixbio.com/patients/
#MetastaticBreastCancerAwarenessDay #breastaware #DYK
The reality of individuals living with #breastcancer doesn't stop when October ends and neither does our commitment to advancing research.
Learn more about our clinical #CDK2 program targeting difficult to treat breast cancer: incyclixbio.com/our-science/
#BreastCancerAwarenessMonth
#DYK: The signs and symptoms of #ovariancancer are subtle and often mistaken for other health issues. Know the signs and get checked: ovarian.org/about-ovarian-ca… #OvarianCancerAwarenessMonth
Ovarian cancer is referred to as a “silent” disease. Symptoms are often vague and misdiagnosed, making awareness even more critical for patients. Join us to spread awareness for #OvarianCancerAwarenessMonth and help detect #ovarian cancer and save lives. ovarian.org/programs-and-res…
Attending ConvergeSouth 2026? Check out a panel featuring our CEO Patrick Roberts, Pharm.D., Ph.D., exploring the future of oncology innovation—from precision treatment approaches to emerging advances like INX-315. We look forward to connecting at #ConvergeSouth! #NCBiotech
Hormone resistance occurs in most metastatic patients. Understanding the biology of ER+/HER2- #breastcancer is critical to help these patients. At Incyclix Bio, our innovative #CDK2-targeted approach aims to address treatment resistance. incyclixbio.com/our-science/
As we approach #NCSD2026, Incyclix Bio honors the strength of cancer survivors facing lifelong challenges after treatment. We’re committed to advancing innovative therapies for when #cancer returns and helping create a brighter future for survivors. #CelebrateLife
Targeting #CDK2 could unlock new options for cancers resistant to current treatments.
Critical advances, including biomarkers like CCNE1 amplification, are accelerating progress.
Incyclix's latest research adds to the momentum behind #CDK2inhibitors: incyclixbio.com/publications…
#DYK, May is #WomenHealthMonth?
#WomensHealth has been historically underfunded and under-researched.
Incyclix is proud to address unmet need in women’s health by advancing the research behind our #CDK2 inhibitor for hard-to-treat breast and ovarian cancer.
April is Cancer Prevention and Early Detection Month. The first line of defense against cancer is prevention and early detection. Know your risk, get screened and reduce your risk and we can create #BetterOutcomes! Visit @preventcancer to learn more: preventcancer.org/
We’re proud to share that Incyclix Bio was named as a winner of the @TriangleBIZJrnl’s 2026 Life Sciences Awards. View the full list here ⬇️ bizjournals.com/triangle/new…
We’re pleased to announce we have secured an additional $5 million for our Series B financing round and the addition of Kseniya Simpson, PhD, and Christy Shaffer, PhD, (Hatteras Venture Partners) to Incyclix’s board. Read more ➡️ incyclixbio.com/news_release…
Innovation is only as strong as the scientific team backing it. Our CEO Patrick Roberts discussed the importance of cultivating long-standing relationships with KOLs and the pathways to grow them in an interview with @ClinicalLeader1. Read more: clinicalleader.com/doc/the-a…
#CDKs are key regulators of critical biological processes supporting cellular proliferation, making them novel targets for #cancer treatment.
At Incyclix, we’re exploring #CDK2 inhibition as a novel approach to treat advanced/resistant cancer. Learn more: incyclixbio.com/our-science/…
30% of #breastcancer will ultimately become metastatic. While CDK4/6 inhibitors have been transformative, there are still patients unresponsive to current therapies. At Incyclix, we're working to fill this gap and make excellent treatment possible for all.
Our focus is advancing treatment for advanced, resistant breast and ovarian cancers, but we acknowledge that addressing the unique needs of everyone is vital to rewriting the future of cancer care. Join us to amplify patient stories for #WorldCancerDay! #UnitedbyUnique
INX-315, our novel #CDK2 inhibitor, was spotlighted in a @Pharmacy_Times article featuring insight from Dr. Shom Goel (@PeterMacCC) on the emerging CDK inhibitors redefining the treatment landscape for CDK4/6 resistant metastatic #breastcancer. pharmacytimes.com/view/how-n… #SABCS25
We’re thrilled to announce our latest addition to our Board of Directors, Kim Blackwell, MD!
Dr. Blackwell is a leading oncology innovator and #breastcancer researcher with over 20 years of drug development experience. Read more: incyclixbio.com/news_release…
Attending #SABCS25?
Don’t miss the poster sessions exploring #CDK2 inhibition as a novel strategy to help close critical gaps in #breastcancer treatment. Exciting science pointing toward new possibilities for patients and clinicians.
More details here🔬: abstractsonline.com/pp8/#!/2…
We’re headed to the 2025 San Antonio Breast Cancer Symposium to connect and discuss the latest advancements at the largest #breastcancer research meeting in the world. See you in San Antonio! #SABCS25
